Company Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.
It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite.
Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Nov 2, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Satyavrat Shukla C.F.A. |
Contact Details
Address: 675 Massachusetts Avenue, 14th Floor Cambridge, Massachusetts 02139 United States | |
| Phone | 857-242-1600 |
| Website | sperotherapeutics.com |
Stock Details
| Ticker Symbol | SPRO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001701108 |
| CUSIP Number | 84833T103 |
| ISIN Number | US84833T1034 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ankit Mahadevia M.D., MBA | Co-Founder and Chairman of the Board |
| Satyavrat Shukla C.F.A. | President, Chief Executive Officer and Director |
| Timothy Keutzer | Chief Operating Officer |
| Esther P. Rajavelu | Chief Financial Officer and Chief Business Officer |
| Ted Jenkins | Vice President and Head of Investor Relations |
| James P. Brady | Chief Human Resource Officer |
| Dr. Kamal Hamed M.B.A., M.D., M.P.H. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | ARS | Filing |
| Apr 16, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 16, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 22, 2024 | EFFECT | Notice of Effectiveness |
| Mar 20, 2024 | UPLOAD | Filing |
| Mar 15, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 15, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 13, 2024 | 10-K | Annual Report |
| Mar 13, 2024 | 8-K | Current Report |